What is BacterioScan?
BacterioScan operates at the intersection of medical technology and clinical efficiency, providing the only FDA-cleared device specifically engineered for rapid urinary tract infection (UTI) detection. By utilizing advanced light-scattering technology, the platform delivers diagnostic results within a 30 to 180-minute window, boasting a 97.7% sensitivity rate and a 99.2% negative predictive value. This technological edge allows healthcare providers to rule out true-negative cases with unprecedented speed, directly mitigating the prevalence of unnecessary antibiotic prescriptions. As a leader in the diagnostic space, BacterioScan is fundamentally reshaping the standard of care for UTI management, reducing systemic healthcare costs while improving patient outcomes through actionable, real-time data.
How much funding has BacterioScan raised?
BacterioScan has raised a total of $9.9M across 4 funding rounds:
Unspecified
$2.1M
Series A
$6M
Unspecified
$1.7M
Debt
$150K
Unspecified (2013): $2.1M, investors not publicly disclosed
Series A (2014): $6M led by Missouri Technology, Warson Capital Partners, and BioGenerator
Unspecified (2015): $1.7M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Key Investors in BacterioScan
Missouri Technology
The Missouri Technology Corporation is a public-private partnership focused on enhancing entrepreneurship and supporting high-tech growth within the life sciences and technology sectors.
Warson Capital Partners
A St. Louis-based firm specializing in capital sourcing, financial restructuring, and mergers and acquisitions for emerging middle-market enterprises.
BioGenerator
BioGenerator is a St. Louis-based organization that fosters innovation by providing both venture capital investment and comprehensive laboratory support for early-stage startups.
What's next for BacterioScan?
With the support of its latest financing, BacterioScan is entering a pivotal phase of commercial expansion and product refinement. The strategic focus will likely center on increasing market penetration within hospital systems and urgent care facilities, where the demand for rapid diagnostic throughput is highest. By optimizing its supply chain and enhancing its diagnostic infrastructure, the company aims to solidify its position as an essential partner in antibiotic stewardship programs. Furthermore, the firm is well-positioned to explore additional diagnostic applications for its light-scattering technology, potentially diversifying its portfolio beyond UTI detection. As the healthcare industry continues to prioritize value-based care, BacterioScan's commitment to affordable, high-accuracy diagnostics will remain a cornerstone of its long-term growth strategy and competitive advantage in the life sciences sector.
See full BacterioScan company page
